Koyfin Home > Directory > Health Care > Abbott Laboratories > Long-Term Debt

Abbott Laboratories Long-Term Debt Chart (ABT)

Abbott Laboratories annual/quarterly Long-Term Debt from 2010 to 2020.
  • Abbott Laboratories Long-Term Debt for the quarter ending September 09, 2020 was $18,349m a 9.20% increase of 1,688m year over year
  • Abbott Laboratories Long-Term Debt for the last 12 months ending September 09, 2020 was $18,349m a 9.20% increase of 1,688m year over year
  • Abbott Laboratories Annual Long-Term Debt for 2019 was $16,661m a -16.19% decrease of -2,698m from 2018
  • Abbott Laboratories Annual Long-Term Debt for 2018 was $19,359m a -40.55% decrease of -7,851m from 2017
  • Abbott Laboratories Annual Long-Term Debt for 2017 was $27,210m a 23.99% increase of 6,529m from 2016
Other Cash Flow Metrics:
  • Abbott Laboratories Cash Flow from Operations for the quarter ending September 09, 2018 was $2,183m a 8.15% increase of 178m year over year
  • Abbott Laboratories Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $1,647m a 6.17% increase of 102m year over year
  • Abbott Laboratories Total Revenue for the quarter ending December 12, 2018 was $7,765m a 4.83% increase of 375m year over year
View Chart On Koyfin

Quarterly ABT Long-Term Debt Data

09/2020$18,349m
06/2020$18,184m
03/2020$16,804m
12/2019$16,661m
09/2019$17,639m
06/2019$18,982m
03/2019$18,902m
12/2018$19,359m
09/2018$19,556m
06/2018$20,053m

Annual ABT Long-Term Debt Data

2019$16,661m
2018$19,359m
2017$27,210m
2016$20,681m
2015$5,871m
2014$3,393m
2013$3,388m
2012$18,085m
2011$12,040m
2010$12,560m